News and publications
NeoPrecis Beats Tumor Mutation Burden as a Predictor of Immunotherapy Response
By combining MHC-I/II neoantigen immunogenicity with tumor clonal architecture, NeoPrecis outperforms TMB across five melanoma and three NSCLC cohorts.
More news

Open Data
Designing a Personalized Cancer Vaccine from Sid Sijbrandij's Data
Designing a Personalized Cancer Vaccine from Sid Sijbrandij's Data

QB3
Teaching Cancer Vaccines What to Target: Invoke Bio Turns to AI
Teaching Cancer Vaccines What to Target: Invoke Bio Turns to AI

bioRxiv Preprint
Learning What Cancer Reveals: Introducing NEMo
Learning What Cancer Reveals: Introducing NEMo

QB3
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
See all
news
